Physician profile
Christopher Morrison
NPI 1548581473
$7,240.74
in general payments reported to CMS, 2019-2025
35 companies · $1,724 in 2025
The $1,724 reported for 2025 was more than what 75% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $740 · 2020: $298 · 2022: $923 · 2023: $1,573 · 2024: $1,983 · 2025: $1,724.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,243 · Education: $36.98.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,243.00 |
| Education | $36.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,923.42 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $969.66 | 2019-2025 | Xifaxan, Trulance, Relistor |
| Takeda Pharmaceuticals U.S.A., INC. | $789.23 | 2019-2025 | Entyvio, Eohilia |
| Janssen Biotech, INC. | $529.38 | 2019-2025 | Stelara, Tremfya, Simponi |
| Regeneron Healthcare Solutions, INC. | $278.36 | 2023-2025 | Dupixent |
| Celgene Corporation | $241.63 | 2022-2024 | Zeposia |
| Qol Medical, LLC | $233.90 | 2023-2025 | Sucraid, Sucraid |
| Pfizer INC. | $231.18 | 2019-2025 | |
| Aimmune Therapeutics, INC. | $225.63 | 2024-2025 | Zenpep |
| Merck Sharp & Dohme LLC | $201.35 | 2019-2024 | Dificid |
| Ironwood Pharmaceuticals, INC | $168.35 | 2022-2024 | Linzess |
| Intra-Sana Laboratories | $150.00 | 2024 | Reltone 200 Mg, Reltone 400 Mg, Glycate |
| Ardelyx, INC. | $138.37 | 2024-2025 | Ibsrela |
| Erbe USA INC | $130.50 | 2020 | |
| Lilly USA, LLC | $122.49 | 2024-2025 | Omvoh |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $108.39 | 2024-2025 | Voquezna |
| Genzyme Corporation | $99.06 | 2023-2024 | |
| Celltrion USA INC. | $98.89 | 2025 | Vegzelma |
| Ferring Pharmaceuticals INC. | $77.49 | 2019-2023 | Rebyota, Cimzia |
| Madrigal Pharmaceuticals | $75.26 | 2024-2025 | Rezdiffra, Resmetirom |
| Braintree Laboratories, INC. | $65.66 | 2019-2023 | Sutab |
| Daiichi Sankyo INC. | $52.41 | 2019-2025 | Injectafer |
| Gilead Sciences, INC. | $49.20 | 2023-2025 | |
| Intercept Pharmaceuticals, INC. | $46.79 | 2019-2024 | |
| Nestle Healthcare Nutrition INC. | $42.29 | 2022-2023 | |
| Ipsen Biopharmaceuticals, INC | $40.37 | 2025 | Iqirvo |
| Boston Scientific Corporation | $40.21 | 2024 | Watchman |
| Allergan, INC. | $24.88 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $19.49 | 2022 | |
| Ge Healthcare | $16.81 | 2025 | |
| Organon LLC | $14.25 | 2024 | |
| Evoke Pharma, INC. | $13.22 | 2023 | Gimoti |
| Romark Laboratories, Lc | $11.55 | 2019 | |
| Ethicon US, LLC | $11.07 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Morrison listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.